Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1

Status

Active not recruiting 4Terminated 1No longer available 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 2

Conditions

Primary Myelofibrosis 4Neoplasms 3Myeloproliferative Disorders 2Leukemia, Myeloid, Acute 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myelomonocytic, Chronic 1

Interventions

ruxolitinib 9navitoclax 4Tacrolimus 4Cyclophosphamide 4Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3venetoclax 2fludarabine phosphate 2fludarabine 2Melphalan 2Busulfan 2veliparib 1selinexor 1pevonedistat 1luspatercept 1letermovir 1itacitinib 1imetelstat 1givinostat hydrochloride 1givinostat 1fedratinib 1elotuzumab 1canakinumab 1avelumab 1Valganciclovir 1Topotecan 1Therapeutics 1Stem Cell Transplantation 1Sirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Primary Myelofibrosis × navitoclax × Clear all
NCT05455294 2026-01-28

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
16 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT04468984 2026-01-09

TRANSFORM-2

AbbVie

Phase 3 Active not recruiting
330 enrolled
Myeloid

Neoplasms, Primary Myelofibrosis

NCT04454658 2025-07-16

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

AbbVie

Phase 1 Active not recruiting
21 enrolled
Myeloid

Neoplasms, Primary Myelofibrosis

NCT04041050 2025-02-14

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

AbbVie

Phase 1 Active not recruiting
85 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Neoplasms, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡